GSA Capital Partners’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-11,807
| Closed | -$41K | – | 1646 |
|
|
2021
Q1 | $41K | Sell |
11,807
-28,365
| -71% | -$88.2K | 0.01% | 1035 |
|
|
2020
Q4 | $101K | Sell |
40,172
-26,500
| -40% | -$57.7K | 0.02% | 1097 |
|
|
2020
Q3 | $141K | Buy |
66,672
+52,761
| +379% | +$125K | 0.02% | 1080 |
|
|
2020
Q2 | $31K | Buy |
+13,911
| New | +$35.8K | 0.02% | 552 |
|
|
2020
Q1 | – | Sell |
-17,593
| Closed | -$46K | – | 1649 |
|
|
2019
Q4 | $46K | Sell |
17,593
-17,200
| -49% | -$51.4K | 0.01% | 1374 |
|
|
2019
Q3 | $125K | Sell |
34,793
-41,107
| -54% | -$145K | 0.02% | 1254 |
|
|
2019
Q2 | $256K | Buy |
75,900
+14,300
| +23% | +$50.4K | 0.03% | 1101 |
|
|
2019
Q1 | $168K | Sell |
61,600
-57
| -0.1% | -$187 | 0.02% | 1272 |
|
|
2018
Q4 | $171K | Hold |
61,657
| – | – | 0.02% | 1138 |
|
|
2018
Q3 | $254K | Sell |
61,657
-44,043
| -42% | -$200K | 0.01% | 1398 |
|
|
2018
Q2 | $549K | Sell |
105,700
-37,700
| -26% | -$230K | 0.03% | 1112 |
|
|
2018
Q1 | $786K | Buy |
143,400
+2,700
| +2% | +$19K | 0.04% | 823 |
|
|
2017
Q4 | $1.15M | Sell |
140,700
-3,391
| -2% | -$32.4K | 0.07% | 517 |
|
|
2017
Q3 | $1.51M | Sell |
144,091
-27,600
| -16% | -$306K | 0.1% | 284 |
|
|
2017
Q2 | $1.9M | Sell |
171,691
-145,240
| -46% | -$1.35M | 0.12% | 177 |
|
|
2017
Q1 | $2.65M | Buy |
316,931
+53,831
| +20% | +$379K | 0.14% | 148 |
|
|
2016
Q4 | $1.83M | Buy |
263,100
+103,292
| +65% | +$659K | 0.11% | 240 |
|
|
2016
Q3 | $813K | Buy |
159,808
+55,300
| +53% | +$330K | 0.04% | 736 |
|
|
2016
Q2 | $624K | Sell |
104,508
-79,519
| -43% | -$441K | 0.03% | 948 |
|
|
2016
Q1 | $837K | Sell |
184,027
-75,500
| -29% | -$336K | 0.05% | 658 |
|
|
2015
Q4 | $1.17M | Sell |
259,527
-16,571
| -6% | -$70K | 0.06% | 581 |
|
|
2015
Q3 | $875K | Buy |
276,098
+31,204
| +13% | +$94.7K | 0.04% | 747 |
|
|
2015
Q2 | $742K | Buy |
244,894
+138,798
| +131% | +$390K | 0.03% | 1109 |
|
|
2015
Q1 | $313K | Buy |
106,096
+30,870
| +41% | +$101K | 0.01% | 1691 |
|
|
2014
Q4 | $334K | Buy |
75,226
+61,881
| +464% | +$295K | 0.02% | 1199 |
|
|
2014
Q3 | $69K | Sell |
13,345
-20,748
| -61% | -$111K | ﹤0.01% | 1643 |
|
|
2014
Q2 | $179K | Buy |
+34,093
| New | +$147K | 0.01% | 1655 |
|
|
2014
Q1 | – | Sell |
-63,393
| Closed | -$185K | – | 1840 |
|
|
2013
Q4 | $185K | Sell |
63,393
-5,100
| -7% | -$12.6K | 0.01% | 1483 |
|
|
2013
Q3 | $173K | Sell |
68,493
-3,700
| -5% | -$8.77K | 0.01% | 1425 |
|
|
2013
Q2 | $150K | Buy |
+72,193
| New | +$159K | 0.02% | 1162 |
|
Other funds holding ENZ
HFA
RAM
EGA
VCA
GSA Capital Partners's ENZ Position: Q2 2021 in Review
GSA Capital Partners sold out of Enzo Biochem, Inc. (ENZ) in Q2 2021, closing a stake of 11,807 shares — an estimated $41K sold.
GSA Capital Partners first reported a position in ENZ in Q2 2013 and held it in 30 quarters. The position peaked at $2.65M in Q1 2017. 72 funds tracked by Wall St. Rank hold ENZ as of Q2 2021.
- GSA Capital Partners reported no remaining Enzo Biochem, Inc. position as of Q2 2021 after selling out during the quarter.
- GSA Capital Partners sold 11,807 Enzo Biochem, Inc. shares in Q2 2021, an estimated $41K.
- GSA Capital Partners first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 30 quarters.
- GSA Capital Partners's Enzo Biochem, Inc. position peaked at $2.65M in Q1 2017.
- 72 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2021.
Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.